Zobrazeno 1 - 7
of 7
pro vyhledávání: '"Pascale Van Belle"'
Autor:
Wivine Burny, Andrea Callegaro, Viviane Bechtold, Frédéric Clement, Sophie Delhaye, Laurence Fissette, Michel Janssens, Geert Leroux-Roels, Arnaud Marchant, Robert A. van den Berg, Nathalie Garçon, Robbert van der Most, Arnaud M. Didierlaurent, On Behalf of the ECR-002 Study Group, Isabelle Carletti, Arnaud Didierlaurent, Meral Esen, Julian Gabor, Edwige Haelterman, Caroline Hervé, Yves Horsmans, Peter Kremsner, Philippe Moris, Tino F Schwarz, Fernanda Tavares da Silva, Pascale Van Belle, Pierre Van Damme, Dirk Zuchner
Publikováno v:
Frontiers in Immunology, Vol 8 (2017)
To elucidate the role of innate responses in vaccine immunogenicity, we compared early responses to hepatitis B virus (HBV) surface antigen (HBsAg) combined with different Adjuvant Systems (AS) in healthy HBV-naïve adults, and included these paramet
Externí odkaz:
https://doaj.org/article/65af7ce2d89547bb915bf9bedc2e9b49
Autor:
Meral Esen, Yves Horsmans, Annick Hens, Fernanda Tavares Da Silva, Nathalie Garçon, Frédéric Clement, Isabelle Carletti, Michel Janssens, Geert Leroux-Roels, Laurence Fissette, Robbert van der Most, Jack Levy, Tino F. Schwarz, Wivine Burny, Pascale Van Belle, Philippe Moris, Arnaud Marchant, Edwige Haelterman, Pierre Van Damme, Peter G. Kremsner, Arnaud M. Didierlaurent, Wolfgang Jilg, Marcelle Van Mechelen, Julian J. Gabor
Publikováno v:
Clinical immunology
Clinical Immunology, Vol. 169, p. 16-27 (2016)
CLINICAL IMMUNOLOGY
Clinical immunology, 169
Clinical Immunology, Vol. 169, p. 16-27 (2016)
CLINICAL IMMUNOLOGY
Clinical immunology, 169
Immunogenicity and safety of different adjuvants combined with a model antigen (HBsAg) were compared. Healthy HBV-naïve adults were randomized to receive HBs adjuvanted with alum or Adjuvant Systems AS01B, AS01E, AS03A or AS04 at Days 0 and 30. Diff
Autor:
Edwige Haelterman, Philippe Moris, Laurent Licini, Jack Levy, Dominique Boutriau, Pascale Van Belle, Silvia Damaso, Pascal Lestrate
Publikováno v:
Human Vaccines & Immunotherapeutics
We assessed the safety, reactogenicity and immunogenicity of a staphylococcal vaccine combining capsular polysaccharides types 5 and 8 (CPS5/8), conjugated to tetanus toxoid (TT), with mutated detoxified α-toxin (AT) and clumping factor A (ClfA). In
Autor:
Michel Janssens, Marcelle Van Mechelen, Nathalie Garçon, Isabelle Carletti, Pierre Vandepapelière, Geert Leroux-Roels, Martine Wettendorff, Yves Horsmans, Pascale Van Belle
Publikováno v:
VACCINE
Background Recombinant hepatitis B surface antigen (HBsAg) was used as a model antigen to evaluate persistence of cellular and humoral immune responses when formulated with three different Adjuvant Systems containing 3- O -desacyl-4′-monophosphoryl
Autor:
Pascale Van Belle, Pierre Vandepapelière, Yves Horsmans, Philippe Moris, Jeanne-Marie Devaster, Vincent Verlant, Jan Poolman, Philippe Hermand, Geert Leroux-Roels, Isabel Leroux-Roels, Isabelle Henckaerts
Publikováno v:
Vaccine. 33:577-584
BackgroundThe protection elicited by polysaccharide pneumococcal vaccines against community-acquired pneumonia in older adults remains debatable. Alternative vaccine targets include well-conserved pneumococcal protein antigens, such as pneumococcal h
Autor:
Pascale Van Belle, Vincent Verlant, Thierry G. Pascal, Magalie Caubet, Karlis Pauksens, Pierre Vandepapelière, Anna Nilsson, Peter Vink, Jan Poolman
Publikováno v:
Clinical and vaccine immunology : CVI. 21(5)
Six vaccine formulations containing AS02 V or alum (aluminum phosphate [AlPO 4 ]) adjuvant with pneumococcal proteins, pneumococcal histidine triad D (PhtD), and/or detoxified pneumolysin (dPly), either as a polysaccharide carrier in an 8-valent pneu
Autor:
Veronika Wertzova, Jeanne-Marie Devaster, Pascale Van Belle, Eva Kaliskova, Bruce L. Innis, Helena Jirincova, Jiří Beran, Martina Havlíčková, Jiří Havlík, Karel Honegr, Varsha K. Jain
Publikováno v:
BMC Infectious Diseases, Vol 9, Iss 1, p 2 (2009)
BMC Infectious Diseases
BMC Infectious Diseases
Background Our aim was to determine the efficacy of a trivalent inactivated split virus influenza vaccine (TIV) against culture-confirmed influenza A and/or B in adults 18 to 64 years of age during the 2005/2006 season in the Czech Republic. Methods